ArticleCurrent infectious disease reports2010
Advances in the Development of Microbicides for the Prevention of HIV Infection.
Article in Current infectious disease reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00074425 (Phase II/IIb Safety and Effectiveness Study of the Vaginal Microbicides BufferGel and 0.5% PRO 2000/5 Gel), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II/IIb Safety and Effectiveness Study of the Vaginal Microbicides BufferGel and 0.5% PRO 2000/5 Gel (P) for the Prevention of HIV Infection in Women
Who cites it
16 citing papers in PubMed.
- Deducing Mucosal Pharmacokinetics and Pharmacodynamics of the Anti-HIV Molecule Tenofovir from Measurements in Blood.Scientific reports · 2019Article
- The Safety of Multiple Flexible Sigmoidoscopies with Mucosal Biopsies in Healthy Clinical Trial Participants.AIDS research and human retroviruses · 2017Article
- Silencing sexually transmitted infections: topical siRNA-based interventions for the prevention of HIV and HSV.Infectious diseases in obstetrics and gynecology · 2014Review
- Sexually transmitted infections and reproductive health morbidity in a cohort of female sex workers screened for a microbicide feasibility study in Nellore, India.Global journal of health science · 2013Article
- Decreased cervical epithelial sensitivity to nonoxynol-9 (N-9) after four daily applications in a murine model of topical vaginal microbicide safety.BMC pharmacology & toxicology · 2012Article
- Hyperimmune bovine colostrum as a low-cost, large-scale source of antibodies with broad neutralizing activity for HIV-1 envelope with potential use in microbicides.Antimicrobial agents and chemotherapy · 2012Article
- Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- Pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques.Antimicrobial agents and chemotherapy · 2012Article
- The future role of rectal and vaginal microbicides to prevent HIV infection in heterosexual populations: implications for product development and prevention.Sexually transmitted infections · 2011Article
- The importance of the vaginal delivery route for antiretrovirals in HIV prevention.Therapeutic delivery · 2011Review
- Microbicides: a new hope for HIV prevention.The Indian journal of medical research · 2011Review
- Using modeling to help understand vaginal microbicide functionality and create better products.Drug delivery and translational research · 2011Article
- Advances in the prevention of heterosexual transmission of HIV/AIDS among women in the United States.Infectious disease reports · 2011Article
- Potential use of rapamycin in HIV infection.British journal of clinical pharmacology · 2010Review
- Structure-activity relationships of polybiguanides with activity against human immunodeficiency virus type 1.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2010Article
- Plant made anti-HIV microbicides--a field of opportunity.Biotechnology advancesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Microbicides are products that can be applied to vaginal or rectal mucosa with the intent of preventing, or at least significantly reducing, the transmission of sexually transmitted infections, including HIV-1. The past 2 or 3 years of microbicide research have generated several disappointments. Large, phase 2B/3 studies failed to demonstrate product efficacy, were stopped prematurely for futility, and in the worst-case scenario possibly demonstrated microbicide-induced harm. The most recently completed efficacy study (HPTN-035) did not reach statistical significance, but did show that use of PRO-2000 was associated with a 30% reduction in HIV acquisition. Current research focuses on much more potent targeted therapy, including reverse transcriptase inhibitors and CCR5 antagonists. Ongoing challenges include optimizing the identification of safety signals in phase 1/2 studies, defining a rationale for advancing products into efficacy studies, and identifying populations with adequate HIV seroincidence rates for these studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.